The cancer patient and cardiology.
- Zamorano JL Department of Cardiology, University Hospital Ramón y Cajal, CiberCV, Madrid, Spain.
- Gottfridsson C Cardiovascular Safety Centre of Excellence, Patient Safety, CMO Organization, AstraZeneca, Gothenburg, Sweden.
- Asteggiano R ESC Council of Cardio-Oncology, Insubria University of Medicine, Varese, Italy.
- Atar D Department of Cardiology, Oslo University Hospital Ulleval, Oslo, Norway.
- Badimon L ESC Advocacy Committee 2018-2020, Director Cardiovascular Programme (ICCC)-IR Hospital de la Santa Creu I Sant Pau, CiberCV, Barcelona, Spain.
- Bax JJ Department of Cardiology, Leiden University Medical Centre, Leiden, the Netherlands.
- Cardinale D Cardio-Oncology Unit, European Institute of Oncology, IRCCS, Milan, Italy.
- Cardone A European Cancer Patient Coalition, Brussels, Belgium.
- Feijen EAM Princess Maxima Centre for Paediatric Oncology, Utrecht, the Netherlands.
- Ferdinandy P Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary.
- López-Fernández T Department of Cardiology, University Hospital La Paz, IdiPAZ, Ciber CV, Madrid, Spain.
- Gale CP Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.
- Maduro JH Department of Radiation Oncology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.
- Moslehi J Cardio-Oncology Program, Vanderbilt University Medical Center, Nashville, TN, USA.
- Omland T Department of Cardiology, Akershus University Hospital, University of Oslo, Oslo, Norway.
- Plana Gomez JC Department of Cardiology, Texas Heart Institute and Baylor College of Medicine, Houston, TX, USA.
- Scott J Exercise Oncology Research Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Suter TM Department of Cardiology, Inselspital, Bern University Hospital, Bern, Switzerland.
- Minotti G Campus Bio-Medico University School of Medicine, Rome, Italy.
- 2020-08-19
Published in:
- European journal of heart failure. - 2020
English
Advances in cancer treatments have improved clinical outcomes, leading to an increasing population of cancer survivors. However, this success is associated with high rates of short- and long-term cardiovascular (CV) toxicities. The number and variety of cancer drugs and CV toxicity types make long-term care a complex undertaking. This requires a multidisciplinary approach that includes expertise in oncology, cardiology and other related specialties, and has led to the development of the cardio-oncology subspecialty. This paper aims to provide an overview of the main adverse events, risk assessment and risk mitigation strategies, early diagnosis, medical and complementary strategies for prevention and management, and long-term follow-up strategies for patients at risk of cancer therapy-related cardiotoxicities. Research to better define strategies for early identification, follow-up and management is highly necessary. Although the academic cardio-oncology community may be the best vehicle to foster awareness and research in this field, additional stakeholders (industry, government agencies and patient organizations) must be involved to facilitate cross-discipline interactions and help in the design and funding of cardio-oncology trials. The overarching goals of cardio-oncology are to assist clinicians in providing optimal care for patients with cancer and cancer survivors, to provide insight into future areas of research and to search for collaborations with industry, funding bodies and patient advocates. However, many unmet needs remain. This document is the product of brainstorming presentations and active discussions held at the Cardiovascular Round Table workshop organized in January 2020 by the European Society of Cardiology.
- Language
-
- English
- Open access status
- bronze
- Identifiers
-
- DOI 10.1002/ejhf.1985
- PMID 32809231
- Persistent URL
- https://sonar.ch/global/documents/201
Statistics
Document views: 80
File downloads:
- Full-text: 0